Dr. Ali El-Ghamrawy, Chairman of the Egyptian Drug Authority (EDA), held a meeting with representatives from Saudi pharmaceutical companies ""Badael"" and ""Al-Batterjee"" to discuss mutual cooperation and investment strategies in the pharmaceutical sector.
During the meeting, Badael, a subsidiary of the Saudi Investment Fund, presented its activities as a leading pharmaceutical company, highlighting its successful manufacturing and expansion experiences. Discussions also covered the company's future investment plans in the Egyptian and regional markets over the next three years, aiming to enhance the penetration of Egyptian pharmaceutical products across the region.
The meeting also focused on developing pharmaceutical export platforms, strengthening industrial integration, and enhancing the global competitiveness of Egyptian pharmaceuticals.
Both parties emphasized the importance of continuous coordination to facilitate investment procedures and promote innovation in the pharmaceutical industry while adhering to the latest regulatory and technical standards. Discussions also underscored the need to support alternative and sustainable pharmaceutical investments, particularly in smoking cessation products and tobacco-free alternatives, contributing to public health goals and improved quality of life.
The meeting was attended by Dr. Mohamed Mostafa, Director of the Quality Department, Dr. Abdullah Al-Jalal, Director of Regulatory Affairs, and Dr. Mahmoud Sayed Ahmed, Chief Marketing Officer, representing Badael. Dr. Mazen MaGed El-Manshawy, CEO of Manapharma, and Dr. Mohamed Mazen, CEO of Al-Batterjee Pharmaceutical Industries, also participated. From EDA, the attendees included Prof. Hanan Amin, Head of the Central Administration for Pharmaceutical Products; Dr. Amany Gawdet, Associate Chairman and Supervisor of the Central Administration for the Chairman’s Office; Dr. Osama Hatem, Associate Chairman for Public Relations and International Cooperation and Supervisor of the Central Administration of Pharmaceutical Policies and Market Access; and Dr. Hamada Gamal, Associate Chairman and General Manager of the General Administration for Human Pharmaceuticals.
This meeting aligns with EDA’s efforts to strengthen collaboration with leading pharmaceutical companies, open new investment opportunities, and support Egypt’s national economy while driving sustainable development in the pharmaceutical industry.